FrancophonIA/ELRC3.0 huggingface dataset:
English: As a precautionary measure, direct contact with the treated dog should be avoided and children should not be allowed to play with a treated animal until the application site is dry.
Estonian: Ettevaatusmeetmena tuleb vältida vahetut kokkupuudet ravimit saanud koeraga ja lapsed ei tohi sellise loomaga mängida, enne kui manustamiskoht on kuivanud.
English: Two field studies were conducted in dogs at veterinary practices in several European countries and different geographic regions.
Estonian: Mitme Euroopa riigi ja eri geograafiliste piirkondade loomakliinikutes toimus kaks koerte väliuuringut.
English: As other products of this group, Prac-tic should not be used in sick animals or dogs that have just recovered from illness.
Estonian: Nagu teisigi selle rühma ravimeid, ei tohi Prac-tici kasutada haigetel ega äsja paranenud koertel.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Prac-tic exceed the risks for the approved indications and recommended that Prac-tic be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustustel on Prac-tici kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Once applied, it remains active for at least 4 weeks.
Estonian: Ravimi ühe manustamise toime kestab vähemalt 4 nädalat.
English: The most common side effects in dogs are local reactions at the place where the product has been applied: change in the fur colour, hair loss and itchiness, as well as change in appearance of the fur (greasy appearance and clumpiness).
Estonian: Tavalisimad kõrvalnähud koertel on paiksed reaktsioonid ravimi manustamiskohal: karvkatte värvuse muutus, karvade väljalangemine ja sügelus, samuti muutused karvakatte välimuses (rasvasus ja pulstumine).
English: If a dog licks the application area, the dog might salivate a lot for a short period.
Estonian: Kui koer lakub manustamiskohta, võib sellele järgneda lühiajaline süljevoolus.
English: Pyriprole, interacts with a receptor involved in transmitting neural impulses (GABA receptor).
Estonian: Püriprool mõjutab üht närviimpulsside edastamise retseptorit (GABA retseptorit).
English: The effectiveness was measured looking at the number of live ticks or number of fleas at various times up to 3 months after application.
Estonian: Efektiivsuse põhinäitaja oli elus puukide või kirpude arv, kusjuures parasiite loendati mitmel korral kuni 3 kuu vältel pärast ravimi manustamist.
English: Dogs from various breeds, age groups and weight that were infested with fleas or ticks were either treated with Prac-tic or with other products authorised in the EU for this indication.
Estonian: Eri tõugu, vanuses ja kaalus koeri, kellel olid kirbud või puugid, raviti kas Prac-tici või muude Euroopa Liidus selleks näidustuseks heakskiidetud ravimitega.
English: The content of the pipette is squeezed onto the skin after parting the fur in one up to three spots between the shoulder blades and down the backline of the dog.
Estonian: Pipeti sisu pigistatakse 1-3 kohas koera seljal abaluude vahele ja piki lülisammast allapoole nahale, olles eelnevalt lükanud karva laiali.
English: Data were provided on the pharmaceutical quality, the tolerance of the product in dogs and the safety in humans (people in contact with the product) and the environment.
Estonian: Ravimi kohta esitati järgmised andmed: farmatseutiline kvaliteet, koerte ravimitaluvus ja ravimi inimohutus (ohutus ravimiga kokkupuutuvatel inimestel) ning keskkonnaohutus.
English: Prac-tic is a spot-on solution that contains pyriprole as active substance.
Estonian: Prac-tic on täpilahus, mis sisaldab toimeainet püriprooli.
English: What is Prac-tic?
Estonian: Mis on Prac-tic?
English: The effectiveness of pyriprole against flea and tick infestations in dogs was investigated in laboratory studies and in field trials.
Estonian: Püriprooli efektiivsust kirpude ja puukide hävitamiseks koertel uuriti labori- ja väliuuringutes.
English: Other information about Prac-tic:
Estonian: Muu teave Prac-tici kohta
English: Why has Prac-tic been approved?
Estonian: Miks Prac-tic heaks kiideti?
English: What is the risk associated with Prac-tic?
Estonian: Mis riskid Prac-ticiga kaasnevad?
English: Skin contact with the pipette content should be avoided.
Estonian: Tuleb vältida pipetisisu sattumist nahale.
English: People with known hypersensitivity to the phenylpyrazole class compounds or any of the excipients should avoid contact with Prac-tic.
Estonian: Fenüülpürasooli klassi ühendite või ravimi mis tahes abiainete suhtes ülitundlikud inimesed peavad vältima kokkupuudet Prac-ticiga.
English: How does Prac-tic work?
Estonian: Kuidas Prac-tic toimib?
English: The results of the field trials showed that Prac-tic is effective in the treatment and prevention of flea and tick infestations in dogs.
Estonian: Väliuuringute tulemustest selgus, et Prac-tic on koertel kirpude ja puukide hävitamiseks ning tõrjeks efektiivne.
English: What benefit has Prac-tic shown during the studies?
Estonian: Milles seisneb uuringute põhjal Prac-tici kasulikkus?
English: Prac-tic is an “ectoparasiticide”, which means that it will kill parasites that live on the skin or in the fur of animals, such as fleas and ticks.
Estonian: Välisparasiidid on parasiidid, kes elavad looma nahal või karvades, näiteks kirbud ja puugid.
English: Skin should be washed and eyes should be rinsed with water, if accidental exposure occurred.
Estonian: Juhuslikult nahale ja silma sattunud aine tuleb eemaldada veega.
English: Prac-tic is used to treat and to prevent tick and flea infestations in dogs.
Estonian: Prac-tici kasutatakse koertel puukide ja kirpude hävitamiseks ja tõrjeks.
English: Adult fleas are killed before they lay eggs; since Prac-tic completely eliminates egg production, it breaks the flea life cycle.
Estonian: Et Practic takistab täielikult kirbumunade tekke, katkestab see kirpude elutsükli.
English: What is Prac-tic used for?
Estonian: Milleks Prac-tici kasutatakse?
English: 50 x 1 tablet(unit dose) 105 tablets
Estonian: 50 x 1 tablett (üksikannus)
English: Name
Estonian: (Väljamõeldud) nimetus
English: This finding was based on the results from 769 patients.
Estonian: See tulemus tugines 769 patsiendi andmetele.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nexavar on 19 July 2006.
Estonian: Euroopa Komisjon andis Nexavari müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. juulil 2006.
English: Nexavar is given as two tablets twice a day, without food or with a meal that is low in fat.
Estonian: Nexavari antakse kaks tabletti kaks korda ööpäevas ilma toiduta või koos väherasvase einega.
English: To manage side effects, treatment may have to be temporarily interrupted or the dose may be reduced.
Estonian: Kõrvalnähtude leevendamiseks tohib ravi ajutiselt katkestada või annust vähendada.
English: • renal cell carcinoma (29 July 2004)
Estonian: • renaaltsellulaarne kartsinoom (29. juuli 2004)
English: The treatment is continued as long as the patient continues to benefit from it without too many side effects.
Estonian: Ravi peab kestma niikaua, kuni see on kasulik, ilma et tekiks liiga palju kõrvalnähte.
English: The summaries of the opinions of the Committee for Orphan Medicinal Products for Nexavar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
Estonian: Harvikravimite komitee arvamuse kokkuvõte Nexavari kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
English: Nexavar has been compared with placebo (a dummy treatment) in three main studies.
Estonian: Nexavari võrreldi platseeboga (näiva ravimiga) kolmes põhiuuringus.
English: Other information about Nexavar
Estonian: Muu teave Nexavari kohta
English: • hepatocellular carcinoma (11 April 2006)
Estonian: • hepatotsellulaarne kartsinoom (11. aprill 2006)
English: The first study involved 602 patients with hepatocellular carcinoma; the second involved 903 patients with advanced renal cell carcinoma in whom one previous anticancer treatment had stopped working; and the third study involved 417 patients with differentiated thyroid carcinoma that had progressed or spread locally or to other parts of the body and did not respond to treatment with radioactive iodine.
Estonian: Esimeses uuringus osales 602 hepatotsellulaarse kartsinoomiga patsienti; teises osales 903 kaugelearenenud renaaltseullulaarse kartsinoomiga patsienti, kellele varasem vähiravi enam ei mõjunud; kolmandas uuringus osales 417 diferentseerunud kilpnäärme kartsinoomiga patsienti, kellel oli vähk progresseerunud või levinud paikselt või mujale organismi ega reageerinud radioaktiivse joodi ravile.
English: The CHMP decided that Nexavar's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Nexavari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Nexavar.
Estonian: See on ravimi Nexavar Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Nexavar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Nexavariga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Nexavar is used to treat patients who have the following diseases:
Estonian: Nexavari kasutatakse järgmiste haiguste ravimiseks:
English: The main measures of effectiveness were how long the patients survived or how long the patients lived without their disease getting worse.
Estonian: Efektiivsuse põhinäitaja oli patsientide elulemus või progresseerumiseta elulemus (kui kaua patsiendid elasid haiguse süvenemiseta).
English: The most common side effects with Nexavar are diarrhoea, rash, alopecia (hair loss), infection, hand foot skin reaction (rash and pain on the palms of the hands and soles of the feet) and fatigue (tiredness).
Estonian: Nexavari kõige sagedamad kõrvalnähud on kõhulahtisus, lööve, alopeetsia, infektsioon, käte ja jalgade nahareaktsioonid (lööve ja valu peopesadel ja jalataldadel) ning väsimus.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nexavar.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the full list of all side effects and restrictions with Nexavar, see the package leaflet.
Estonian: Nexavari kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: This finding was based on the results from all 903 patients, including about 200 who had switched from placebo to Nexavar before the end of the study.
Estonian: See tulemus põhines andmetel, mis saadi 903 Nexavariga ravitud patsiendi põhjal, kelle hulka kuulusid ligikaudu 200 patsienti, kes enne uuringu lõppemist hakkasid saama platseebo asemel Nexavari.
English: Because the numbers of patients with these diseases are low, the diseases are considered ‘rare', and Nexavar was designated an ‘orphan medicine' (a medicine used in rare diseases).
Estonian: Et nende haigustega patsientide on vähe ja need haigused esinevad harva, nimetati Nexavar harvikravimiks.
English: These enzymes can be found in some receptors on the surface of cancer cells, where they are involved in the growth and spread of cancer cells, and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels.
Estonian: Proteiinkinaase leidub teatud retseptorites vähirakkude pinnal, kus nad osalevad vähirakkude kasvus ja levikus, ning kasvajaid varustavates veresoontes, kus nad osalevad uute veresoonte tekkes.
English: By blocking these enzymes, Nexavar can reduce the growth of cancer cells and cut off the blood supply that keeps cancer cells growing.
Estonian: Neid ensüüme blokeerides vähendab Nexavar vähirakkude kasvu ja peatab nende kasvu toetava verevarustuse.
English: • advanced renal cell carcinoma (a type of kidney cancer) when anticancer treatment with interferon alfa or interleukin 2 has failed or cannot be used;
Estonian: • kaugelearenenud renaaltsellulaarne kartsinoom (teatud neeruvähiliik), kui eelnev ravi alfainterferooniga või interleukiin-2-ga on ebaõnnestunud või ei sobi.
English: The most important serious side effects are myocardial infarction (heart attack) or ischaemia (reduced oxygen supply to the heart), gastrointestinal perforation (a hole that develops in the wall of the gut), drug-induced hepatitis (a disease of the liver), haemorrhage (bleeding) and hypertension or hypertensive crisis (high blood pressure).
Estonian: Kõige raskemad kõrvalnähud on müokardiaalne infarkt või isheemia (südamelihase verevarustushäired), gastrointestinaalne perforatsioon (sooleseina ava), ravimitest tingitud hepatiit (maksahaigus), veritsus, kõrgvererõhk ja hüpertensiivne kriis (vererõhu tõus).
English: EPAR summary for the public sorafenib
Estonian: Kokkuvõte üldsusele sorafeniib
English: Nexavar is a cancer medicine that contains the active substance sorafenib.
Estonian: Nexavar on vähiravim, mis sisaldab toimeainena sorafeniibi.
English: Why has Nexavar been approved?
Estonian: Miks Nexavar heaks kiideti?
English: What is Nexavar?
Estonian: Mis on Nexavar?
English: Treatment with Nexavar should be supervised by doctors who have experience of anticancer treatments.
Estonian: Ravi Nexavariga peab jälgima vähiravis kogenud arst.
English: What is the risk associated with Nexavar?
Estonian: Mis riskid Nexavariga kaasnevad?
English: • papillary thyroid cancer and follicular thyroid cancer (13 November 2013) The full EPAR for Nexavar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Nexavari kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: • hepatocellular carcinoma (a type of liver cancer);
Estonian: • hepatotsellulaarne kartsinoom (teatud maksavähiliik);
English: Nexavar was more effective than placebo in increasing how long the patients survived or how long the patients lived without their disease getting worse.
Estonian: Nexavar oli patsientide üldise või progresseerumiseta elulemuse pikendamisel platseebost efektiivsem.
English: The patients taking Nexavar lived for longer without their disease getting worse (167 days, around five and a half months) than those who took placebo (84 days, around three months).
Estonian: Võrreldes patsientidega, kes said platseebot (84 päeva, ligikaudu kolm kuud), elasid Nexavari võtnud patsiendid kauem, enne kui nende haigus hakkas süvenema (167 päeva, ligikaudu viis ja pool kuud).
English: What benefit has Nexavar shown during the studies?
Estonian: Milles seisneb uuringute põhjal Nexavari kasulikkus?
English: How is Nexavar used?
Estonian: Kuidas Nexavari kasutatakse?
English: In the study in differentiated thyroid carcinoma, the patients taking Nexavar lived for an average of 10.8 months without their disease getting worse, compared with 5.8 months in those taking placebo.
Estonian: Diferentseerunud kilpnäärme kartsinoomi uuringus oli Nexavari saanud patsientide keskmine elulemus 10,8 kuud, platseebot saanud patsientidel aga 5,8 kuud.
English: How does Nexavar work?
Estonian: Kuidas Nexavar toimib?
English: In the study of renal cell carcinoma, the patients taking Nexavar survived for an average of 19.3 months, compared with 15.9 months in those taking placebo.
Estonian: Renaaltsellulaarse kartsinoomi uuringus oli Nexavari saanud patsientide keskmine elulemus 19,3 kuud, platseebot saanud patsientidel aga 15,9 kuud.
English: The active substance in Nexavar, sorafenib, is a protein kinase inhibitor.
Estonian: Nexavari toimeaine sorafeniib on proteiinkinaasiinhibiitor ehk aine, mis blokeerib teatud ensüüme proteiinkinaase.
English: In the study of hepatocellular carcinoma, the patients taking Nexavar survived for an average of 10.7 months, compared with 7.9 months in those taking placebo.
Estonian: Hepatotsellulaarse kartsinoomi uuringus oli Nexavari saanud patsientide keskmine elulemus 10,7 kuud, platseebot saanud patsientidel aga 7,9 kuud.
English: What is Nexavar used for?
Estonian: Milleks Nexavari kasutatakse?
English: How has Nexavar been studied?
Estonian: Kuidas Nexavari uuriti?
English: • differentiated thyroid carcinoma (a type of cancer originating from the follicular cells of the thyroid gland) when the cancer has progressed or spread locally or to other parts of the body and does not respond to treatment with radioactive iodine.
Estonian: kui vähk on progresseerunud või levinud paikselt või organismis mujale ega reageeri radioaktiivse joodiga ravile.
English: The full EPAR for Levetiracetam Actavis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Levetiracetam Actavis kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Actavis on 3 October 2011.
Estonian: Euroopa Komisjon andis ravimi Levetiracetam Actavis müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 3. oktoobril 2011.
English: • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Estonian: • primaarsed generaliseerunud toonilis-kloonilised episoodid (rasked epilepsiaepisoodid, millega kaasneb ka teadvusekaotus) vähemalt 12-aastastel patsientidel, kellel on idiopaatiline generaliseerunud epilepsia (epilepsia liik, mille tekkepõhjust peetakse geneetiliseks).
English: For more information about treatment with Levetiracetam Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimi Levetiracetam Actavis ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Actavis.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The Committee recommended that Levetiracetam Actavis be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Levetiracetam Actavis müügiloa.
English: This helps Levetiracetam Actavis to stabilise electrical activity in the brain and prevent seizures.
Estonian: See aitab ravimil stabiliseerida aju elektrilist talitlust ja ennetada epilepsiaepisoode.
English: Because Levetiracetam Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Levetiracetam Actavis on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Levetiracetam Actavis.
Estonian: See on ravimi Levetiracetam Actavis Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP concluded that, in accordance with EU requirements, Levetiracetam Actavis has been shown to have comparable quality and to be bioequivalent to Keppra.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Levetiracetam Actavis võrdväärne kvaliteet ja bioekvivalentsus ravimiga Keppra.
English: Levetiracetam Actavis can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Estonian: Ravimit Levetiracetam Actavis tohib kasutada ainsa ravimina vähemalt 16-aastastel patsientidel, kellel on äsja diagnoositud epilepsia, et ravida sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalseid episoode.
English: Because Levetiracetam Actavis is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Estonian: Et Levetiracetam Actavis on geneeriline ravim, piirdusid uuringud katsetega, milles näidati ravimi bioekvivalentsust võrdlusravimiga Keppra.
English: This means that Levetiracetam Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
Estonian: See tähendab, et Levetiracetam Actavis on sarnane võrdlusravimiga Keppra, millel juba on Euroopa Liidus müügiluba.
English: Other information about Levetiracetam Actavis
Estonian: Muu teave ravimi Levetiracetam Actavis kohta
English: Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Keppra korral, ületab ravimi Levetiracetam Actavis kasulikkus sellega kaasnevad riskid.
English: Levetiracetam Actavis can also be used as an add-on to other anti-epileptic medicines to treat:
Estonian: Ravimit Levetiracetam Actavis tohib kasutada ka teiste epilepsiaravimite lisaravimina, et ravida järgmisi haigusseisundeid:
English: In patients aged between six months and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day.
Estonian: 6-kuulistel kuni 17-aastastel patsientidel kehamassiga alla 50 kg on algannus 10 mg kehamassi kg kohta kaks korda ööpäevas, seda annust tohib suurendada annuseni 30 mg/kg, mida manustatakse kaks korda ööpäevas.
English: Levetiracetam Actavis tablets are swallowed with liquid.
Estonian: Ravimi Levetiracetam Actavis tabletid neelatakse koos vedelikuga.
English: When Levetiracetam Actavis is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Estonian: Ravimi Levetiracetam Actavis lisamisel teisele epilepsiaravimile vähemalt 12-aastastel patsientidel kehamassiga üle 50 kg on algannus 500 mg kaks korda ööpäevas.
English: What is Levetiracetam Actavis?
Estonian: Mis on Levetiracetam Actavis?
English: Why has Levetiracetam Actavis been approved?
Estonian: Miks Levetiracetam Actavis heaks kiideti?
English: Levetiracetam Actavis is a medicine that contains the active substance levetiracetam.
Estonian: Levetiracetam Actavis on ravim, mis sisaldab toimeainena levetiratsetaami.
English: When Levetiracetam Actavis is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Estonian: Ravimi Levetiracetam Actavis kasutamisel ainsa ravimina on algannus 250 mg kaks korda ööpäevas, seda suurendatakse kahe nädala pärast annuseni 500 mg kaks korda ööpäevas.
English: Levetiracetam Actavis is a ‘generic medicine'.
Estonian: Levetiracetam Actavis on geneeriline ravim.
English: How has Levetiracetam Actavis been studied?
Estonian: Kuidas ravimit Levetiracetam Actavis uuriti?
English: What are the benefits and risks of Levetiracetam Actavis?
Estonian: Milles seisneb ravimi Levetiracetam Actiavis kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Levetiracetam Actavis used?
Estonian: Kuidas ravimit Levetiracetam Actavis kasutatakse?
English: The active substance in Levetiracetam Actavis, levetiracetam, is an anti-epileptic medicine.
Estonian: Ravimi Levetiracetam Actavis toimeaine levetiratsetaam on epilepsiaravim.
English: How does Levetiracetam Actavis work?
Estonian: Kuidas Levetiracetam Actavis toimib?